Poland· PL-100015062

Clostilbegyt

A clomifene product containing clomifeni citras, registered in Poland by Egis Pharmaceuticals PLC. The same ATC class is registered in 12 of our 19 countries.

ATC G03GB02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedClostilbegytATCG03GB02REGISTER NO.PL-100015062PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Clomifene is registered in 12 of 19 countries.

Countries holding a registration under ATC G03GB02 (clomifene), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Clomifene · ATC G03GB02

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of clomifene costs, country by country.

Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.10 in Italy to $0.76 in United States — a ×7.3 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Clomifene · price per daily dose (9 mg)

USD · FX 28 Sept 2026

  • US United States$0.76 (acquisition cost)
  • FR France$0.14
  • IT Italy$0.10
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Clomifeni citras
Manufacturer
Egis Pharmaceuticals PLC
Country
Poland (PL)
ATC code
G03GB02
ATC class
Clomifene
Defined daily dose
9 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909990156412
  • gtin
    05909991369736

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for clomifene.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Clomifene · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • BexaroteneL01XF03severe
  • BexarotenL01XX25severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Clomifene in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All clomifene products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

  • Austria · Clomiphen Viatris
  • Belgium · Clomid
  • Bulgaria · Клостилбегит
  • Cyprus · Duinum, Fertilan
  • Czechia · Clostilbegyt
  • Germany · Clomifen Ratiopharm
  • Spain · Omifin
  • France · Clomid
  • United Kingdom (Northern Ireland) · Clomid, Clomifene Wockhardt Uk
  • Greece · Clomiphene Citrate Anfarm
  • Hungary · Clostilbegyt
  • Ireland · Clomid
  • Italy · Clomid
  • Lithuania · Clostilbegyt
  • Luxembourg · Clomid
  • Latvia · Clostilbegyt
  • Netherlands · Clomifeencitraat Cf
  • Portugal · Dufine
  • Romania · Clostilbegyt
  • Slovakia · Clostilbegyt

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f31efd89-a9c1-4672-8407-aed1896a1dd9
GET /v1/drugs/f31efd89-a9c1-4672-8407-aed1896a1dd9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "50 mg",
  "packaging": "05909990156412 ¦ Rp ¦ 2595\n10 tabl.\n05909991369736 ¦ Rp ¦ 127696\n20 tabl.",
  "substance": "Clomifeni citras 50 mg",
  "common_name": "Clomifeni citras",
  "pl_product_id": "100015062",
  "pozwolenie_nr": "01564",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}

See everything about clomifene.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.